RAPID C-19 was set up early in the pandemic. Its aim was to get treatments for COVID-19 to patients quickly and safely as part of temporary emergency pandemic arrangements.
RAPID C-19’s role in reviewing potential COVID-19 treatments has now ended because we have moved back to routine commissioning arrangements for these treatments.
You can read more about NICE’s guidance and advice on COVID-19.
About RAPID C-19
RAPID C-19 monitored emerging trial evidence on the clinical effectiveness of potential COVID-19 treatments during the pandemic. This meant that evidence could be assessed rapidly and COVID‑19 treatments made available to patients if the evidence of benefit was strong.
RAPID C-19 was a collaboration between NICE and these organisations:
- NHS England
- Medicines and Healthcare products Regulatory Agency
- National Institute for Health and Care Research
- Scottish Medicines Consortium (Healthcare Improvement Scotland)
- All Wales Therapeutics and Toxicology Centre
- All Wales Medicines Strategy Group
- Department of Health in Northern Ireland
- Antivirals and Therapeutics Task Force at the Department of Health and Social Care.